Iron deficiency anemia - Section 11

Mechanisms, mishaps and manipulation of iron uptake

Cavan Bennett1,2, Sant-Rayn Pasricha1,2,3
1 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; 2 Department of Medical Biology, The University of Melbourne, Parkville, Australia; 3 Clinical and Diagnostic Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Australia

Take home messages

- Disorders in systemic iron regulation or intestinal iron absorption can result in functional or absolute iron deficiency or iron overload.
- A generation of pharmaceuticals are now entering clinical trials aimed at manipulating systemic iron regulation to alleviate pathologic iron loading or depletion.

Introduction

Insights into mechanisms of iron absorption and systemic iron handling have improved understanding of the pathophysiology of a range of clinical conditions that cause iron deficiency (or iron withholding from the plasma, ‘functional iron deficiency’) or iron overload, and have led to rationally-designed novel therapeutics that may transform management of iron withholding or overload states, some of which are now entering clinical trials. Here, we review recent advances in iron-related physiology, pathology, and pharmaceuticals.

Current state of the art

Mechanisms of iron uptake and distribution

To prevent iron deficiency and overload, iron utilization and losses must be balanced by iron uptake (Fig. 1). Systemic iron distribution is governed by the hepatic-derived hormone hepcidin. Hepcidin binds to the only known cellular iron exporter, ferroportin, to both occlude its channel1 and cause its internalization and degradation, thus controlling entry of iron to the plasma from the duodenum (absorption) and reticuloendothelial system (recycling). Hepcidin is transcriptionally (epigenetically via HDAC3)2 regulated by BMP/SMAD signaling (iron availability via iron sensing in the liver, erythropoietic demand via erythroferrone3,4 and acute serum iron deprivation3), and inflammation (IL6, JAK/STAT signaling) (Fig. 1).

Mishaps

Iron deficiency. Here we focus on clinical factors that impair iron uptake through either impaired luminal iron function or increased hepcidin expression.

Impaired luminal iron absorption causes iron deficiency. Defective acidification of the intestinal contents impairs solubility of ferric iron in the intestine, limiting absorption.5 This poses a risk for patients who have undergone gastrectomy, and those who undergo gastric bypass for treatment of obesity. Helicobacter Pylori infection may cause iron deficiency6 by impairing the acidic gut environment and promoting gastrointestinal bleeding. Chronic gastric acid suppression (ie, proton pump inhibition or histamine receptor antagonism)7 can increase risk of iron deficiency.

Intestinal (especially duodenal) dysfunction impairs iron absorption. Coeliac disease causes immune-mediated destruction of the intestinal absorptive surface resulting in diminished absorption of numerous nutrients including iron.8 Iron deficiency may indicate occult coeliac disease and screening for this condition is now widely suggested for iron deficient patients. Other disorders of the intestinal functional surface (eg, environmental enteropathy in developing countries), or intestinal absorptive area (eg, resections due to inflammatory bowel disease) may promote iron deficiency.

Iron absorption and organ utilization is diminished in systemic conditions which physiologically or pathologically raise hepcidin (functional iron deficiency). Anemia of chronic disease occurs in inflammatory conditions (infections, cancer, autoimmune diseases) that increase hepcidin expression via IL6 (also IL22) mediated JAK-STAT signaling or directly abrogate ferroportin transcription via TLR signaling.11 Among clinically-well but subclinically inflamed populations, elevated hepcidin is an important cause of iron deficiency: for example, in sub-Saharan Africa where subclinical plasmodium infection is common12 and...
Figure 1. Systemic iron metabolism and therapeutics against the hepcidin-ferroportin axis. Therapeutics that alter iron levels via the hepcidin-FPN axis are highlighted in red. Iron circulates in the plasma predominantly bound to transferrin (Tf; green squares). Iron reaches the plasma via absorption of dietary iron by duodenal enterocytes and recycling of iron from senescent erythrocytes by reticuloendothelial macrophages. The mechanism of dietary iron entry to enterocytes depends on the type of iron. Non-heme ferric iron (Fe$^{3+}$; black circles) is reduced to ferrous iron (Fe$^{2+}$; grey circles) by the ferrireductase DCYTB and transported across the apical membrane by DMT1. Heme iron (red circles) entry is probably via an undiscovered transporter. Once internalized, iron from both sources is exported to the bloodstream through the basolateral membrane via the only known iron exporter, ferroportin (FPN; red channel). The ferroxidase hephaestin (HEPH) co-localizes with FPN and oxidizes exported Fe$^{2+}$ to Fe$^{3+}$ allowing it to bind Tf. Reticuloendothelial macrophages phagocytose and degrade senescent erythrocytes, releasing heme into the phagolysosome, which is then exported into the cytoplasm and degraded. Iron can then be stored in the macrophages in ferritin (grey hexagons) or released via FPN where it will circulate bound to Tf. Systemic iron distribution is controlled by the hepatic derived hormone hepcidin (grey stars), which binds, occludes and leads to the degradation of FPN. Hepcidin expression is determined at the transcriptional level by BMP/SMAD and JAK/STAT (via IL-6/IL-22) signaling. The BMP/SMAD pathway is negatively regulated by TMPRSS6, which in low iron conditions cleaves hemoujuvelin (HJV, a BMP co-receptor), inhibiting hepcidin expression. Immature red cells (erythroblasts), which accumulate during increased erythropoiesis, produce erythroferrone (ERFE; blue hexagons). ERFE negatively regulates hepcidin expression by dampening BMP/SMAD signaling. BMP = bone morphogenetic protein, BMPR = BMP receptor, CP = ceruloplasmin, DCYTB = duodenal cytochrome B, DMT1 = divalent metal transporter 1, EPO = erythropoietin, ERFE = erythroferrone, FPN = ferroportin, HAMP = hepcidin, HEPH = hephaestin, HIF = hypoxia inducible factor, HJV = hemoujuvelin, IL-6 = interleukin 6, IL-R = interleukin receptor, JAK = Janus Kinase, STAT3 = signal transducer and activator of transcription 3, Tf = transferrin, TMPRSS6 = transmembrane serine protease 6.
Iron overload. Genetic mutations impairing hepcidin expression or function can result in excess iron uptake and iron overload. Mutations affecting the HFE gene are most common but of low penetrance, with rarer mutations in HJV, TFR2, and HAMP producing a more severe phenotype. Mutations that quantitative- ly affect ferroportin or inhibit its degradation by hepcidin also result in iron overload (reviewed).

Inherited (ie, haemoglobinopathies) and acquired (eg, myelodysplastic syndromes) genetic haematologic conditions can produce ineffective erythropoiesis. The expanded erythroid pool creates enormous iron demand and causes suppression of hepcidin likely via erythroblast production of erythroferrone. Together with hypoxia-mediated upregulation of duodenal DMT1, this results in increased iron absorption and overload.

**Future perspectives**

**Therapeutic manipulations in iron handling**

At least 16 therapeutics entering clinical trials aim to increase or reduce plasma iron entry by manipulating the hepcidin-ferroportin axis (Table 1 and Fig. 1).

**Downregulation of hepcidin.** Several drugs prevent hepcidin function. PRS-080, an Anticalin protein linked to linear polyethylene-glycol, binds hepcidin and inhibits its function; it is being trialed in patients with chronic kidney disease. Similarly, NOX-H94, a PEGylated anti-hepcidin L-RNA oligonucleotide inactivates hepcidin after binding, inhibited serum iron suppression in anemia of inflammation experimental models. LY2787106 is a neutralizing hepcidin monoclonal antibody which has shown safety and efficacy in patients with cancer-related anemia. Several drugs prevent hepcidin degradation and stabilizes FPN on the cell surface. It raised iron levels but not hemoglobin in a Phase I study in renal patients. LY2928057, a humanized FPN antibody, inhibits hepcidin function by protecting ferroportin from hepcidin-induced degradation and stabilizes FPN on the cell surface. It raised iron levels but not hemoglobin in a Phase I study in renal patients. Drugs that decrease hepcidin expression include: LY3113593, a humanized BMP6 monoclonal antibody, inhibits hepcidin function by protecting ferroportin from hepcidin-induced degradation and stabilizes FPN on the cell surface. It raised iron levels but not hemoglobin in a Phase I study in renal patients. Drugs that decrease hepcidin expression include: LY3113593, a humanized BMP6 monoclonal antibody, inhibits hepcidin function by protecting ferroportin from hepcidin-induced degradation and stabilizes FPN on the cell surface. It raised iron levels but not hemoglobin in a Phase I study in renal patients.

---

**Table 1**

Therapeutic agents in clinical trial that influence plasma iron levels.

| Therapeutic agent | Company | Administration route | Acts on | Effect on plasma iron | Clinical trials | Reference |
|-------------------|---------|----------------------|---------|-----------------------|----------------|----------|
| Siltuximab        | Multiple | Intravenous          | IL-6    | Decrease              | NCT01183598    | Isaacs et al.24 |
| Tocilizumab       | Multiple | Intravenous          | IL-6 receptor | Increase | NCT01024036 | Casper et al.25 |
| LJP-401           | La Jolla Pharmaceutical Company | Subcutaneous | Ferroportin | Decrease | NCT03381833, NCT03396704 | Lai et al.27 |
| PTC-300           | Protagonist Therapeutics | Subcutaneous | Ferroportin | Decrease | NCT0380220 | Nichols et al.26 |
| IONIS-TMPRSS6-Lux | Ionis Pharmaceuticals | Subcutaneous | TMPRSS6 | Decrease | NCT03165864 | Guo et al.27 |
| SLN124            | Silence Therapeutics | Subcutaneous | TMPRSS6 | Decrease | CTA to be submitted in 2019 | Altamura et al.28 |
| VIT-2763          | Vifor Pharma | Oral | Ferroportin | Decrease | Phase-I completed | http://www.viforpharma.com/∼/media/Files/V/Vifor-Pharma/documents/en/media-releases/2019/0r-vifor-pharma-ferroportin-inhibitor-en.pdf |
| Sotatercept       | Multiple | Subcutaneous | Actin receptor | Decrease | NCT01464164, NCT01712308 | Komrokji et al.32, Cappellini et al.29 |
| Luspatercept      | Multiple | Subcutaneous | Actin receptor | Decrease | NCT03194542, NCT03342404 | Platzbecker et al.29 |
Upregulation of hepcidin. Therapeutics that increase hepcidin levels or function aim to alleviate iron loading conditions. LJPC-401 is a synthetic full-length hepcidin which has entered Phase 2 clinical trials for β-thalassemia and haemochromatosis, while PTG-300 is a hepcidin mimetic which has likewise entered clinical trials for β-thalassemia. Both drugs induce reductions in serum iron in human Phase 1 studies, and in both cases non-limiting local injection site reactions appeared to be the chief adverse effect.

Inhibition of hepatic TMPRSS6 upregulates hepcidin expression. At least 2 molecules with therapeutic potential that silence TMPRSS6 mRNA translation have been developed. IONIS-TMPRSS6-LRx is a ligand conjugated TMPRSS6 silencing molecule that upregulates hepcidin in preclinical models and has entered trials for thalassaemia. Likewise, SLN124 is a conjugated GalNac siRNA targeting TMPRSS6 which has shown pre-clinical activity in thalassaemia models with clinical trials planned in the near future. Beyond agents acting on hepcidin, VI-2763 is a small molecule inhibitor of FPN and therefore replicates hepcidin function, and completed a Phase-I clinical trial in October 2018. Activin receptor ligand traps (Sotatercept, Luspatercept) have preclinical and clinical activity in diseases of ineffective erythropoiesis which indirectly counteracts hepcidin suppression.

Conclusions

New understanding of the molecular pathways governing iron homeostasis has led to a greater appreciation of the pathophysiology of iron related disorders and a pipeline of rationally designed novel therapeutics against the hepcidin-FPN axis.

References

1. Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131:899.
2. Pasricha SR, Lim PJ, Duarte TL, et al. Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. Nat Commun. 2017;8:403.
3. Kautz L, Jung G, Valore EV, et al. Identification of erythроferone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:670–674.
4. Areesz J, Foy N, McHugh K, et al. Erythroferone inhibits the induction of hepcidin by BMPs. Blood. 2018;125:1472–1477.

Characterizes the putative mechanism for erythроferone in the liver.

5. Arujo I, Pennato M, Nai A, et al. Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice. Haematologica. 2019;104:e78–e90.
6. Jacobs A, Miles PM. Role of gastric secretion in iron absorption. Gut. 1969;10:226–229.
7. Ferraz AAB, Carvalho MRC, Siqueira LT, et al. Micronutrient deficiencies following sleeve gastrectomy and Roux-en-Y gastric bypass. Rev Bras Cir. 2018;45:e2016.
8. Monzon H, Forne M, Esteve M, et al. Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin. World J Gastroenterol. 2013;19:4166–4171.
9. Lam JR, Schneider JL, Quesenberry CP, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152:821–829, e821.
10. Freeman HJ. Iron deficiency anaemia in celiac disease. World J Gastroenterol. 2015;21:9233–9238.
11. Guida C, Altamura S, Klein FA, et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferraemia. Blood. 2015;125:2265.
12. Cercamondi CI, Egli IM, Abouandjoune E, et al. Allebrle Plasmadium falciparum parasitemia decreases absorption of fortification iron but does not affect systemic iron utilization: a double stable-isotope study in young Beninese women. Am J Clin Nutr. 2010;92(6):1383–1392.
13. Sanad M, Osman M, Gharib A. Obesity modulate serum hepcidin and treatment outcome of iron deficiency anaemia in children: a case control study. Ital J Pediatr. 2011;37:34.
14. Benyamin B, Ferreira MA, Willemsen G, et al. Common variants in Tmprss6 are associated with iron status and erythrocyte volume. Nat Genet. 2009;41:1173–1175.

Describes how variants in Tmprss6 can influence red blood cell parameters.

15. Pantopoulos K. Inherited disorders of iron overload. Front Nutr. 2018;5:103–1103.
16. Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassaemia. Blood. 2015;126:2031–2037.
17. Anderson ER, Taylor M, Xue X, et al. Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci U S A. 2013;110:E4922–4930.

Describes the role of a hepcidin independent mechanism for iron loading in thalassaemia.

18. Moebius U, Feurer W, Fenzl E, et al. A Phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS-080#022. Results from a randomized, placebo controlled, double-blind study following single administration to healthy subjects. Blood. 2015;126:536.
19. Schwöbel F, van Eijk JT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-194 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013;121:2311–2315.
20. Vadihan-Raj S, Abonour R, Goldman JW, et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10:73.
21. Barrington F, Sheetz MJ, Callies S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-ferroportin antibody in patients with anemia due to chronic renal failure. Blood. 2016;127:1280.
22. Peterson P, Soh KK, Lee YS, et al. ALK2 inhibition Via TP-0184 abrogates inflammation-induced hepcidin expression and is a potential therapeutic for anemia of chronic disease (Abstract). Blood. 2015;126:273.
23. Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25:564–572.
24. Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15:R204.
25. Casper C, Chaturvedi S, Munsli N, et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castlemane disease. Clin Cancer Res. 2015;21:4294–4304.
26. Nicholls A, Lickliter J, Tozzi L, et al. Hepcidin mimetic ptg-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects. Stockholm: European Haematology Association 2018.
27. Lal A, Piga A, Viprakasit V, et al. A phase 1, open-label study to determine the safety, tolerability, and pharmacokinetics of escalating doses of LJPC-401 (synthetic human hepcidin) in patients with iron overload (Abstract). Paper presented at: The 23rd European Hematology Association Congress; 14-17 June 2018; Stockholm, Sweden in press.
28. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013;123:1531–1541.

Characterizes a new clinical approach to treating patients with iron overload conditions.

29. Altamura S, Altamura S, Mukcenthaler M1, et al. SLN124, a Galnc-siRNA conjugate targeting Tmprss6, for the treatment of iron overload and ineffective erythropoiesis such as in beta-thalassemia. Blood. 2018;132 (Suppl 1):2340.
30. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat Med. 2014;20:398–407.
31. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408–414.
32. Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5:e63–e72.
33. Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 2019;104:477–484.
34. Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338–1347.
35. Peterson P, Kim W, Haws H, et al. The ALK-2 Inhibitor, TP-0184, demonstrates high distribution to the liver contributing to significant preclinical efficacy in mouse models of anemia of chronic disease (Abstract). Blood. 2016;128:263.